Table 3.

Antitumor activity in evaluable patients

Characteristic	Total (N = 221)
Best overall response by central review, n (%)
CR	22 (10.0)
CRu	8 (3.6)
PR	60 (27.1)
Stable disease	38 (17.2)
PD	64 (29.0)
Not evaluable	2 (0.9)
Not available	9 (4.1)
Unknown (missing or no response assessment)	18 (8.1)
ORR (CR + CRu + PR) by central review, n (%)	90 (40.7); (95% CI, 34.2-47.5)
DoR, median (95% CI), mo	9.1 (7.4-10.8)
PFS, median (95% CI), mo	4.6 (3.2-5.6)
OS, median (95% CI), mo	16.3 (13.1-22.6)
Kaplan-Meier OS estimates at 12 mo (95% CI)	0.58 (0.51-0.64)
Kaplan-Meier OS estimates at 24 mo (95% CI)	0.39 (0.32-0.46)